- Home
- LFWD vs SNSE Comparison
LFWD vs SNSE Comparison
Compare LFWD & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- SNSE
- Stock Information
- Founded
- LFWD 2001
- SNSE 2005
- Country
- LFWD Israel
- SNSE United States
- Employees
- LFWD N/A
- SNSE N/A
- Industry
- LFWD
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- SNSE Health Care
- Exchange
- LFWD NYSE
- SNSE Nasdaq
- Market Cap
- LFWD 13.7M
- SNSE 12.5M
- IPO Year
- LFWD 2014
- SNSE 2021
- Fundamental
- Price
- LFWD $1.54
- SNSE $0.52
- Analyst Decision
- LFWD Strong Buy
- SNSE Strong Buy
- Analyst Count
- LFWD 1
- SNSE 3
- Target Price
- LFWD $13.00
- SNSE $4.33
- AVG Volume (30 Days)
- LFWD 696.5K
- SNSE 756.4K
- Earning Date
- LFWD 02-25-2025
- SNSE 02-26-2025
- Dividend Yield
- LFWD N/A
- SNSE N/A
- EPS Growth
- LFWD N/A
- SNSE N/A
- EPS
- LFWD N/A
- SNSE N/A
- Revenue
- LFWD $25,002,000.00
- SNSE N/A
- Revenue This Year
- LFWD $87.01
- SNSE N/A
- Revenue Next Year
- LFWD $47.64
- SNSE N/A
- P/E Ratio
- LFWD N/A
- SNSE N/A
- Revenue Growth
- LFWD 173.28
- SNSE N/A
- 52 Week Low
- LFWD $1.41
- SNSE $0.38
- 52 Week High
- LFWD $7.84
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- LFWD 43.19
- SNSE 52.01
- Support Level
- LFWD $1.83
- SNSE $0.48
- Resistance Level
- LFWD $4.00
- SNSE $0.57
- Average True Range (ATR)
- LFWD 0.35
- SNSE 0.05
- MACD
- LFWD -0.05
- SNSE 0.00
- Stochastic Oscillator
- LFWD 2.75
- SNSE 52.36
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.